Search research articles
Contact Us
Filters
Showing results (21-30 of 50) with videos related to
Page
of 5
Sort By:
Journal of Alzheimer'S Disease : JAD
|
July 5, 2021
Classification, Prediction, and Concordance of Cognitive and Functional Progression in Patients with Mild Cognitive Impairment in the United States: A Latent Class Analysis
Julie Mouchet, Keith A Betts, Mihaela V Georgieva, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
June 9, 2022
In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model
Roxana Aldea, Hans Peter Grimm, Ronald Gieschke, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 17, 2016
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations
Barbara Klughammer, Wolfram Brugger, Federico Cappuzzo, et al.
Angiogenesis
|
July 12, 2014
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy
Sanne de Haas, Paul Delmar, Aruna T Bansal, et al.
Angiogenesis
|
February 22, 2014
Genetic markers of bevacizumab-induced hypertension
Diether Lambrechts, Matthieu Moisse, Paul Delmar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 9, 2012
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial
Eric Van Cutsem, Sanne de Haas, Yoon-Koo Kang, et al.
Alzheimer'S Research & Therapy
|
December 14, 2019
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis
Gregory Klein, Paul Delmar, Nicola Voyle, et al.
The Lancet. Oncology
|
May 22, 2012
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
Diether Lambrechts, Bart Claes, Paul Delmar, et al.
Molecular Cancer Therapeutics
|
September 17, 2009
Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients
Windy Berkofsky-Fessler, Tri Q Nguyen, Paul Delmar, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
July 20, 2024
Statistical considerations when estimating time-saving treatment effects in Alzheimer's disease clinical trials
Guoqiao Wang, Gary Cutter, Neil P Oxtoby, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 50) with videos related to
Sort By:
Page
of 5
Journal of Alzheimer'S Disease : JAD
|
July 5, 2021
Classification, Prediction, and Concordance of Cognitive and Functional Progression in Patients with Mild Cognitive Impairment in the United States: A Latent Class Analysis
Julie Mouchet, Keith A Betts, Mihaela V Georgieva, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
June 9, 2022
In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model
Roxana Aldea, Hans Peter Grimm, Ronald Gieschke, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 17, 2016
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations
Barbara Klughammer, Wolfram Brugger, Federico Cappuzzo, et al.
Angiogenesis
|
July 12, 2014
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy
Sanne de Haas, Paul Delmar, Aruna T Bansal, et al.
Angiogenesis
|
February 22, 2014
Genetic markers of bevacizumab-induced hypertension
Diether Lambrechts, Matthieu Moisse, Paul Delmar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 9, 2012
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial
Eric Van Cutsem, Sanne de Haas, Yoon-Koo Kang, et al.
Alzheimer'S Research & Therapy
|
December 14, 2019
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis
Gregory Klein, Paul Delmar, Nicola Voyle, et al.
The Lancet. Oncology
|
May 22, 2012
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
Diether Lambrechts, Bart Claes, Paul Delmar, et al.
Molecular Cancer Therapeutics
|
September 17, 2009
Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients
Windy Berkofsky-Fessler, Tri Q Nguyen, Paul Delmar, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
July 20, 2024
Statistical considerations when estimating time-saving treatment effects in Alzheimer's disease clinical trials
Guoqiao Wang, Gary Cutter, Neil P Oxtoby, et al.
Page
of 5